An open-label phase 2 study of the safety and efficacy of glufosfamide in ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2015
At a glance
- Drugs Glufosfamide (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2008 Status changed from recruiting to discontinued (because of lack of efficacy and enrollment challenges) according to a Threshold Pharmaceuticals media release.
- 02 Feb 2007 Status changed from initiated to recruiting.